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Abstract: 
The article presents the results of a potential mutagenicity studying of a new drug from the group of erythropoietin, 
carbamylateddarbepoetin. The study was performed using DNA-comet assay in mice, and in micronucleus test. As a 
positive control there were used mice which had been injected with genotoxicantmethylmethane sulfonate at a dose 
of 40 mg/kg and as a negative control there were mice after administration of equivalent doses of a placebo. The 
results showed that the mutagenic effect of the drug in single (3.59±1.02) dosing and three times (4.0±0.78) dosing 
had not been different from the mutagenic effect of placebo (4.39±1.34). Micronucleus test was performed using a 
cytogenetic damage of bone marrow cells and checking the appearance of polychromatophil cells, containing 
micronuclei. It was established that carbamylateddarbepoetin within stated doses according to the used test, has no 
a potential carcinogenic effect. 
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INTRODUCTION: 
A search for innovative molecules and its safety 
inspection are important tasks of pharmacology. Each 
new drug must undergo a toxicological evaluation, 
then there is an obligatory regard to its allergenic and 
carcinogenic effects. 
A significant problem is natural or synthesized 
innovative molecules [1, 2], with potentially 
mutagenic properties, which are able to give them in 
the combined action of genotoxicants. Thus, its safety 
study is performed in pharmacological targets [3, 4], 
models in vivo [5, 6], the study of pharmacokinetic 
parameters [7, 8] and clinical studies [9]. Information 
about the impact of new drugs on spontaneous and 
induced mutagenesis obtained in studies on 
mammalian cells in vitro and in vivo, is always 
relevant [10, 11]. In several studies of non-toxic 
substances such as e.g. vitamins there were suddenly 
revealed comutagenic and mutagenic effects, 
explaining their autoxidation, accompanied by the 
initiation of free-radical oxidation and change in 
redox potential. Therefore, potential genotoxicity 
testis necessary for low-toxicity substances such as 
drugs of the human erythropoietin, both natural and 
recombinant. Some studies demonstrate 
antimutagenic properties of erythropoietin, which are 
associated with its ability to inhibit the processes of 
free radical-induced oxidation [12], other scientific 
works indicate undesirable side effects [13]. In this 
regard, the question of the possible influence of 
antioxidants on chromosomal variability remains 
open. Not so long ago, there has been patented a new 
drug in this group, the carbamylated darbepoetin 
made by carbamylation of all amino acid residues of 
lysine, included in the molecule darbepoetin and 
carbamylated amino acid residue of alanine in the N-
terminal of this protein - 9C-DEPO, which is 
hyperglycosylated derivant of the human 
recombinant erythropoietin [14]. This drug has a 
great pharmacological potential, because the 
molecule was modified to not have a negative impact 
on the hematocrit and to retain therapeutic properties. 
This study was performed according to the approved 
"Guidelines for preclinical research" [15]. 
The aim of this study was to evaluate the DNA-
damaging activity and cytogenetic damage ofthe 
carbamylateddarbepoetin. 
 
MATERIALS AND METHODS 
The study was performed in BALB/cmale mice 
weighing 18-20 g at the age of 8-12 weeks. Each 
experimental group included 6 animals. Animals 
were randomized to either experimental and control 
groups after adaptation period and examination, 
excluding the inclusion in the experiment of sick and 
injured animals. The basic rules of management and 
care consistent with the standards outlined in the 
“Guide for the care and use of laboratory animals” 
(National Academy press; Washington, D.C., 2011), 
the rules approved by state standard 53434 – 2009 
"Principles of good laboratory practice" and the 
International recommendations of the European 
Convention for the protection of vertebrate animals 
using for experimental and other scientific purposes 
(ETSN 124, Strasbourg, 22.06.1998). 
The study drug was given as a single dose 
subcutaneously in maximal volume of 1 ml (subtoxic 
dose) and multi dose deliveryfor 4 days 
subcutaneouslyexpressed in a human daily 
therapeutic dose not to exceed 50 µg/kg. The mice of 
the control group (negative control) were 
administered equivalent volume of placebo. In the 
micronucleus test as the positive control the animals 
were irradiated at a dose of 20 roentgens per hour, 
with known cytogenetic effect. In the DNA-comet 
assay as a positive control there were used the mice 
which had been injected intraperitoneally with 
genotoxicantmethylmethane sulfonate at the dose of 
40 mg/kg, for a period of 3 hours. 
Sampling of the bone marrow (micronucleus test) and 
blood (DNA-comet assay) was performed 24 hours 
after the last administration of the test substances. 
The DNA-comet assay. For analysis we used 
peripheral blood of mice obtained by incising the tip 
of the tail. The blood aliquots sampling (10 µl) of 
each animal was performed no later than 24 hours 
after the completion of the drug administration. 
Whole blood was mixed with an equal volume of 
RPMI-1640 medium (without L-glutamine) and 
carefully layered on a gradient mixture of fikoll 
solution with a density of 1.077 and centrifuged at 
400 g for 40 min. The ring of mononuclear cells 
formed on the phase interface was carefully taken 
with a pipette and washed twice with RPMI-
1640mediumand centrifugation at 400 g for 10 min. 
After the second washing, the precipitate had been 
diluted with RPMI-1640 medium to a cell 
concentration of 1-5х105/cc and placed until use in a 
refrigerator at 4ºC. 
The cell suspension in a volume of 60 µl was added 
to the test tube with 240 µl of 0.9% solution of low 
melting agarose (melt temperature<420C) in 
phosphate saline buffer (FSB), heated to 42ºC 
(microthermostat "Termite", Russia) and 
resuspended. Then 60 µl agarose solution with cells 
was applied to pre-coated with 1% universal agarose 
glass slides, covered with cover glass and placed on 
ice. Further, all operations were performed in a 
darkened room under yellow light. After 
solidification of the agarose (about 10 minutes) cover 
glasses were carefully removed, microscope slides 
were placed in a staining cuvette (Schifferdecker 
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type), filled in pre-cooled to + 4ºC lysing buffer (10 
mMTris-HCl [pH 10], 2.5 MNaCl, 100 mMEDTA-
Na2, 1 % TritonX-100, 10% DMSO) and incubated 
for at least 1 hour. After lysis ending the microscope 
slides were transferred into the electrophoresis 
chamber (SubCell GT, “Bio-Rad”). The chamber was 
filled with electrophoresis buffer (300 mMNaOH, 1 
mM EDTA-Na2, pH>13) and the microscope slides 
were incubated for 20 minutes to implement the 
alkali-labile sites and alkaline denaturation of DNA. 
Electrophoresis was performed for 20 minutes at a 
field strength of 1V/cm and a current of ~300 mA. 
After electrophoresis, the microscope slides were 
transferred to the staining cuvette and fixed in 70% 
ethanol solution for 15 minutes. After fixing the 
microscope slides were dried and stored at room 
temperature before analysis.  
Immediately prior to microscopy, the microscope 
slides were stained with the fluorescent dye SYBR 
Green I (1:10000 in TE buffer with 50% glycerol) for 
20 minutes in a dark. Analysis was performed on 
epifluorescence microscope Eclipse Ti-S (Nikon, 
Japan) combined with a digital high resolution 
camera DS-Fi2 (Nikon, Japan) at x200 power. The 
received DNA comets images were analyzed using 
the software CASP 1.2.2. As an indicator of DNA 
damage there was used the percentage of DNA in 
DNA comet tail (%of DNA in tail). With each 
microscope slide there were analyzed at least 100 
cells. Obtained data were compared with the data for 
the negative (solvent) and positive (methylmethane 
sulfonate) controls [16, 17]. 
The micronucleus test. There was evaluated the 
cytogenetic damage of bone marrow cells by the 
appearance of polychromatophil cells containing the 
micronuclei. Euthanasia of mice was performed by 
decapitation 24 h after administration of the test 
substance or radiation. According to the standard 
method there were prepared cell films of the bone 
marrow. From astragalus there was removed the bone 
marrow in 24-well plate for cell cultures, each well 
was added with 200 µl DMEM medium with 10% 
fetal calf serum. The resulting suspension was 
pipetted on microscope glasses and smeared. The 
microscope slides were stained with the 
Romanowsky-Giemsa dye, allowing to differentiate 
polychromatophil cells and normochromatic 
erythrocytes. In each experimental group from one 
mouse there were analyzed 3 microscope slides, 
counting 1000 polychromatophil cells from each 
slide. 
Count of the polychromatophil cells with micronuclei 
was carried out using theoptical microscope Eclipse 
E100 (Nikon, Japan) with immersion lens at 1000 
power. The criterion of cytogenetic damage level was 
the percentage of the cells with micronuclei.  
The results were processed using Microsoft Office 
Excel 2016. There were calculated mean, standard 
error of the mean, statistical significance between 
groups was assessed by Student t-test. 
 
RESEARCH RESULTS: 
During the study with DNA-comet assay there was 
processed dataset, which showed no DNA damage in 
the animal groups which had been administrated with 
carbamylateddarbepoetin (single dose subcutaneously 
in maximal volume of 1 ml (subtoxic dose) and multi 
dose delivery for 4 days subcutaneously at the dose 
of 50 µg/kg). The animals of the negative control 
group that were administered with the placebo, there 
are no DNA damage. Pair-wise comparison of the 
obtained data with the negative control did not reveal 
any statistically significant differences (Fig. 1, 2, 3 
and table 1). In the group of positive control 
methylmethane sulfonate administration led to a 
statistically significant increase in DNA damage 
(p<0.001) in all the investigated samples in 
comparison with the negative control (Fig. 4 and 
table 1). 
 
Table 1: The influence of carbamylateddarbepoetin on the DNA damage level in mononuclear blood cells of 
the mice, negative and positive controls 
Group %of DNA in tail 
The negative control, placebo 4.39±1.34 * 
The drug, 1 ml 3.59±1.02 * 
The drug,50 µg/kg 4.0±0.78 * 
The positive control, methylmethane sulfonate 21.41±1.88 
* - p<0.001 in comparison with the positive control 
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Fig 1. Photomicrography of acellnucleotid of the 
animal administrated with 1 ml of the drug 
(%TDNA=3.59); ×200. 
Fig 2. Photomicrography of acellnucleotid of the 
animal administrated with 50 µg/kg of the drug 
(%TDNA=4.00); ×200. 
  
Fig 3. Photomicrography of acellnucleotid of the 
animal administrated with the placebo 
(%TDNA=4.39); ×200. 
Fig 4. Photomicrography of acellnucleotid of the 
animal administrated with methylmethane 
sulfonate(%TDNA=21.41); ×200. 
 
Analysis of the micronucleus test results showed that 
the carbamylateddarbepoetin in the studied 
concentrations (single dose subcutaneously in 
maximal volume of 1 ml (subtoxic dose) and multi 
dose delivery for 4 days subcutaneously at the dose 
of 50 µg/kg) and negative control did not cause the 
cytogenetic damage in the bone marrow cells. In the 
group of positive control, the radiation of the animals 
resulted in the cytogenetic damage of the bone 
marrow cells, which there were identified the 
polychromatophil cells with micronuclei (table 2). 
Table 2: The influence of the drug on release of the polychromatophil cells with micronuclei in the bone 
marrow of the mice 
Variants Number 
of the 
mice 
Number of the 
analyzed 
polychromatophil 
cells 
Number of the 
polychromatophil 
cells with 
micronuclei 
The 
polychromatophil 
cells with 
micronuclei,% 
The drug, 1 ml 6 3000 16.67±5.61 0.55±0.19* 
The drug,50 µg/kg 6 3000 17.3±6.41 0.58±0.22* 
The negative control, placebo 6 3000 18.0±4.43 0.60±0.14* 
The positive control, X-ray 6 3000 151.5±11.31 5.05±0.38 
*p ≤ 0.01 in comparison with the positive control. 
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CONCLUSION: 
Mutagens can be various factors that cause changes 
in the chromosome structure. Biological substances 
and drugs on their basis are rarely mutagenic; 
however, some products of metabolism can be 
mutagens (e.g., oxidation products of lipids). To 
correct the primary genetic structure damage caused 
by mutagens in cells there are a number of system 
recovery, or reparation of the genetic damage. 
However, during the reparation a part of the primary 
damage can be saved and lead to mutations, which 
clinically are very rare. So there was set one of the 
most important task of a preclinical study to evaluate 
the potential mutagenic effect. The 
carbamylateddarbepoetin in the studied 
concentrations (single dose subcutaneously in 
maximal volume of 1 ml (subtoxic dose) and multi 
dose delivery for 4 days subcutaneously at the dose 
of 50 µg/kg) did not cause the genotoxic effect in the 
bone marrow cells and blood. Micronucleus test 
revealed that, the drug in the studied concentrations 
(single dose subcutaneously in maximal volume of 1 
ml (subtoxic dose) and multi dose delivery for 4 days 
subcutaneously at the dose of 50 µg/kg) did not cause 
the cytogenetic damage in the bone marrow cells. 
Thus, the aggregate of the conducted researches we 
can conclude that the drug carbamylateddarbepoetin 
has no mutagenic properties. 
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